Hasane Ratni

Hasane Ratni has a long history of work experience in the pharmaceutical industry. Hasane started their career in 2002 as an Expert Scientist and Project Leader Discovery Chemistry (Neuroscience and Rare Disease) and Section Head, Medicinal Chemistry (Neuroscience, Ophtalmology and Rare Disease) at F. Hoffmann-La Roche Ltd. In 2005, they joined Chugai Pharmaceuticals as a Medicinal Chemist. In 2018, they returned to F. Hoffmann-La Roche Ltd as an Expert Scientist and Project Team Leader. In 2020, they were promoted to Distinguished Scientist and Project Team Leader. Hasane is currently Vice-President, Chemistry, at Skyhawk Therapeutics, a position they have held since 2022.

Hasane Ratni completed post-doctoral studies at Université de Tokyo from 2001 to 2002. From 1997 to 2001, they obtained a Doctor of Philosophy (Ph.D.) in Organic Chemistry from the University of Geneva. Hasane also obtained a D.E.A (Master degree) Multinational de chimie moleculaire from École Polytechnique in 1998.